Over 2,000 Ozempic, Zepbound Lawsuits Allege Serious Side Effects

Over 2,000 lawsuits have been filed in U.S. courts against manufacturers Novo Nordisk and Eli Lilly alleging serious side effects from GLP-1 receptor agonist drugs like Ozempic, Wegovy, Mounjaro, and Zepbound, used for diabetes and weight loss. Plaintiffs claim these companies failed to adequately warn users about risks including gastroparesis (stomach paralysis), intestinal obstruction, vomiting, gallbladder disease, and vision loss, particularly non-arteritic anterior ischemic optic neuropathy (NAION). The litigation, consolidated as MDL No. 3094 in Pennsylvania federal court, is currently in the discovery phase, which could extend into 2026 due to the large volume of cases and the complexity of proving causation. Medical experts acknowledge that while most patients tolerate these drugs well, the delayed gastric emptying effect may contribute to rare but severe gastrointestinal complications. Regulators have updated product labels to reflect some of these risks, especially for newer drugs like Zepbound, which has rapidly gained attention since its 2023 approval. Manufacturers deny wrongdoing and assert that their product information complies with federal standards, but lawsuits continue to grow amid mounting legal and public scrutiny.